Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer
Nature Cell Biology2016Vol. 18(8), pp. 897–909
Citations Over TimeTop 1% of 2016 papers
Dawid Walerych, Kamil Lisek, Roberta Sommaggio, Silvano Piazza, Yari Ciani, Emiliano Dalla, Katarzyna Rajkowska, Katarzyna Gawęda-Walerych, Eleonora Ingallina, Claudia Tonelli, Marco J. Morelli, Angela Amato, Vincenzo Eterno, Alberto Zambelli, Antonio Rosato, Bruno Amati, Jacek R. Wiśniewski, Giannino Del Sal
Related Papers
- → Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma(2015)56 cited
- → The novel 2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells(2015)47 cited
- → Abstract 1768: Chloroquine potentiates carfilzomib but not bortezomib effects on myeloma cells(2015)1 cited
- → Overcoming Proteasome Inhibitor Resistance in Multiple Myeloma Using the XPO1: Inhibitor Selinexor(2015)
- → Carfilzomib: A New Proteasome Inhibitor for Treatment of Multiple Myeloma(2011)